Chemomab Therapeutics Ltd. (CMMB)

Market Cap	12.96M -50.6%
Revenue (ttm)	n/a
Net Income	-7.45M
EPS	-1.07
Shares Out	7.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,686
Open	1.735
Previous Close	1.720
Day's Range	1.710 - 1.840
52-Week Range	1.350 - 5.520
Beta	0.61
Analysts	Buy
Price Target	15.00 (+733.33%)
Earnings Date	May 14, 2026

About CMMB

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: CMMB
• Website: https://www.chemomab.com

Analyst Summary

According to 2 analysts, the average rating for CMMB stock is "Buy." The 12-month stock price target is $15.0, which is an increase of 733.33% from the latest price.

Price Target

$15.0

(733.33% upside)

Analyst Consensus: Buy